Antiphospholipid and antiendothelial antibodies

Area of Science:

• Immunology
• Rheumatology
• Autoimmune Diseases

Background:

• Antiphospholipid antibodies (aPL) and antiendothelial cell antibodies (AECA) are investigated as serological markers in systemic autoimmune diseases.
• aPL show prognostic value for recurrent thrombosis and fetal loss in systemic lupus erythematosus and primary antiphospholipid syndrome.
• AECA are suggested as markers for immune-mediated vascular damage, supported by experimental and epidemiological studies.

Purpose of the Study:

• To review the role of antiphospholipid and antiendothelial cell antibodies in systemic autoimmune diseases.
• To discuss the diagnostic and prognostic significance of these antibodies.
• To highlight the evolving landscape of diagnostic tests and the challenges in assay standardization.

Main Methods:

• Review of existing literature and studies on antiphospholipid and antiendothelial cell antibodies.
• Analysis of data regarding their association with thrombosis, fetal loss, and vascular damage.
• Discussion of current and emerging diagnostic methodologies.

Main Results:

• Antiphospholipid antibodies are established prognostic markers for thrombosis and fetal loss.
• Emerging diagnostic tests expand the detection of antiphospholipid antibodies beyond cardiolipin.
• Antiendothelial cell antibodies show promise as markers for vascular damage, though assays require standardization.

Conclusions:

• Antiphospholipid and antiendothelial cell antibodies are crucial serological markers in autoimmune disease diagnostics and prognostics.
• Advancements in testing are improving the detection of antiphospholipid antibodies.
• Standardization of antiendothelial cell antibody assays is necessary for widespread clinical application.